Hexokinase 2 promotes tumor growth and metastasis by regulating lactate production in pancreatic cancer

Oncotarget

Volumn 8, Issue 34, 2017, Pages 56081-56094

  Anderson, Marybeth ^a   Marayati, Raoud ^a   Moffitt, Richard ^a   Yeh, Jen Jen ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Glycolysis; Hexokinase 2; Metastasis; Pancreatic cancer

Indexed keywords

HEXOKINASE; HEXOKINASE 2; LACTIC ACID; UNCLASSIFIED DRUG; VASCULOTROPIN A;

AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GLYCOLYSIS; HUMAN; HUMAN CELL; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIMARY TUMOR; PROTEIN FUNCTION; TUMOR PROMOTION; UPREGULATION;

EID: 85029114921     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9760     Document Type: Article

References (51)

1. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis D, Chen H, Feuer E and Cronin Ke. (2013). SEER cancer statistics review, 1975-2010. Based on November 2012 SEER data submission, posted to the SEER web site
2. Ryan DP, Hong TS and Bardeesy N. Pancreatic adenocarcinoma. New England Journal of Medicine. 2014; 371:1039-1049
3. Yeh JJ and Der CJ. Targeting signal transduction in pancreatic cancer treatment. Expert Opinion on Therapeutic Targets. 2007; 11:673-694
4. Bryant KL, Mancias JD, Kimmelman AC and Der CJ. KRAS: feeding pancreatic cancer proliferation. Trends in Biochemical Sciences. 2014; 39:91-100
5. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL and Tan M. Emerging metabolic targets in cancer therapy. Frontiers in Bioscience: a Journal and Virtual Library. 2011; 16:1844-1860
6. Blum R and Kloog Y. Metabolism addiction in pancreatic cancer. Cell Death and Disease. 2014; 5:e1065
7. Guillaumond F, Iovanna JL and Vasseur S. Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways. Archives of Biochemistry and Biophysics. 2014; 545:69-73
8. Ying H, Kimmelman A, Lyssiotis C, Hua S, Chu G, Fletcher-Sananikone E, Locasale J, Son J, Zhang H, Coloff J, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik J, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012; 149:656-670
9. Deeb SS, Malkki M and Laakso M. Human hexokinase II: sequence and homology to other hexokinases. Biochemical and biophysical research communications. 1993; 197:68-74
10. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. Journal of Experimental Biology. 2003; 206:2049-2057
11. Katabi MM, Chan HLB, Karp SE and Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Human Gene Therapy. 1999; 10:155-164
12. Patra K, Wang Q, Bhaskar P, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller W, Allen E, Jha A, Smolen G, Clasquin M, Robey R and Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013; 24:213-228
13. Mathupala S, Ko Y and Pedersen P. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006; 25:4777-4786
14. Mathupala SP, Ko YH and Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect? and a pivotal target for effective therapy. Seminars in cancer biology. 2009; 19:17-24
15. Smith T. Mammalian hexokinases and their abnormal expression in cancer. British Journal of Biomedical Science. 2000; 57:170-178
16. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C and Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. The Journal of Experimental Medicine. 2011; 208:313-326
17. Yoshino H, Enokida H, Itesako T, Kojima S, Kinoshita T, Tatarano S, Chiyomaru T, Nakagawa M and Seki N. Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Science. 2013; 104:1567-1574
18. Gershon TR, Crowther AJ, Tikunov A, Garcia I, Annis R, Yuan H, Miller CR, Macdonald J, Olson J and Deshmukh M. (2013). Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer & Metabolism: BioMed Central, pp. 2
19. Ogawa H, Nagano H, Konno M, Eguchi H, Koseki J, Kawamoto K, Nishida N, Colvin H, Tomokuni A, Tomimaru Y, Hama N, Wada H, Marubashi S, Kobayashi S, Mori M, Doki Y, et al. The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. Molecular and Clinical Oncology. 2015; 3:563-571
20. Chaika NV, Yu F, Purohit V, Mehla K, Lazenby AJ, DiMaio D, Anderson JM, Yeh JJ, Johnson KR, Hollingsworth MA and Singh PK. Differential expression of metabolic genes in tumor and stromal components of primary and metastatic loci in pancreatic adenocarcinoma. PloS one. 2012; 7:e32996
21. Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, Boudreau A, Mroue R, Corson L, OBrien T, Qing J, Sampath D, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proceedings of the National Academy of Sciences. 2015; 112:E4410-E4417
22. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine. 2011; 17:500-503
23. Cheng W, Yang T and Anastassiou D. Development of a prognostic model for breast cancer survival in an open challenge environment. Science Translational Medicine. 2013; 5:181ra150
24. Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SGH, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, Iacobuzio-Donahue CA, et al. Virtual microdissection identifies distinct tumor-and stromaspecific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics. 2015; 47:1168-1178
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005; 102:15545-15550
26. Joost H-G, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schãrmann A, Seino S and Thorens B. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. American Journal of Physiology-Endocrinology and Metabolism. 2002; 282:E974-E976
27. Hsu PP and Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134:703-707
28. Adeva M, González-Lucán M, Seco M and Donapetry C. Enzymes involved in l-lactate metabolism in humans. Mitochondrion. 2013; 13:615-629
29. Mori S, Chang JT, Andrechek ER, Matsumura N, Baba T, Yao G, Kim JW, Gatza M, Murphy S and Nevins JR. Anchorageindependent cell growth signature identifies tumors with metastatic potential. Oncogene. 2009; 28:2796-2805
30. Latham T, Mackay L, Sproul D, Karim M, Culley J, Harrison DJ, Hayward L, Langridge-Smith P, Gilbert N and Ramsahoye BH. Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression. Nucleic Acids Research. 2012; 40:4794-4803
31. Zetter BR. Angiogenesis and tumor metastasis. Annual Review of Medicine. 1998; 49:407-424
32. Schoenfeld J, Lessan K, Johnson N, Charnock-jones D, Evans A, Vourvouhaki E, Scott L, Stephens R, Freeman T, Saidi S, Tom B, Weston G, Rogers P, Smith S and Print C. Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. Angiogenesis. 2004; 7:143-156
33. Elkin M and Vlodavsky I. (2001). Tail Vein Assay of Cancer Metastasis. Current Protocols in Cell Biology: John Wiley & Sons, Inc.)
34. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ and Kurek R. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Molecular Cancer Research. 2009; 7:1438-1445
35. Hamabe A, Yamamoto H, Konno M, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Nishida N, Kawamoto K, Koseki J, Doki Y, Mori M and Ishii H. Combined evaluation of hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1a in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis. Cancer Science. 2014; 105:1100-1108
36. Lee SH, Jeong D, Han Y-S and Baek MJ. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Annals of Surgical Treatment and Research. 2015; 89:1-8
37. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Ketones and lactate "fuel? tumor growth and metastasis. Cell Cycle. 2010; 9:3506-3514
38. Baumann F, Leukel P, Doerfelt A, Beier CP, Dettmer K, Oefner PJ, Kastenberger M, Kreutz M, Nickl-Jockschat T, Bogdahn U, Bosserhoff A-K and Hau P. Lactate promotes glioma migration by TGF-β2-dependent regulation of matrix metalloproteinase-2. Neuro-Oncology. 2009; 11:368-380
39. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW and Mueller-Klieser W. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. International Journal of Radiation Oncology*Biology*Physics. 2001; 51:349-353
40. Xian Z-Y, Liu J-M, Chen Q-K, Chen H-Z, Ye C-J, Xue J, Yang H-Q, Li J-L, Liu X-F and Kuang S-J. Inhibition of LDHA suppresses tumor progression in prostate cancer. Tumour Biology. 2015; 36:8093-8100
41. Kato Y, Lambert CA, Colige AC, Mineur P, Noël A, Frankenne F, Foidart J, Baba M, Hata R, Miyazaki K and Tsukuda M. Acidic extracellular pH induces matrix metalloproteinase-9 expression in mouse metastatic melanoma cells through the phospholipase D-mitogenactivated protein kinase signaling. Journal of Biological Chemistry. 2005; 280:10938-10944
42. Xu L, Fukumura D and Jain R. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanims of low pH-induced VEGF. Journal of Biological Chemistry. 2002; 277:11368-11374
43. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F and Lisanti MP. Ketones and lactate increase cancer cell "stemness? driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle. 2011; 10:1271-1286
44. Sonveaux P, Copetti T, De Saedeleer CJ, Végran F, Verrax J, Kennedy KM, Moon EJ, Dhup S, Danhier P, Frérart F, Gallez B, Ribeiro A, Michiels C, Dewhirst MW and Feron O. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PloS one. 2012; 7:e33418
45. Shi Q, Le X, Wang B, Abbruzzese J, Xiong Q, He Y and Xie K. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 2001; 20:3751-3756
46. Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ and Yeh JJ. Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation. Molecular cancer therapeutics. 2014; 13:122-133
47. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468:968-972
48. Martin TD, Samuel JC, Routh ED, Der CJ and Yeh JJ. Activation and Involvement of Ral GTPases in Colorectal Cancer. Cancer Research. 2011; 71:206-215
49. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED and Beresford-Smith B. Xenome-a tool for classifying reads from xenograft samples. Bioinformatics. 2012; 28:172-178
50. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R and Salzberg S. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biology. 2013; 14:R36
51. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature Protocols. 2012; 7:562-578